Prevention And Treatment Of Chronic Heart And Kidney Disease Via Epidemiological, Pharmacol Device And Cell-Based Approaches
Funder
National Health and Medical Research Council
Funding Amount
$5,795,334.00
Summary
Heart failure describes where the heart cannot pump adequately to meet the needs of the body. This condition has a high mortality despite recent advances in therapy, therefore, there is an urgent need for new approaches to this condition. The present grant aims to: (1) identify patients at high-risk for future development of this condition where early intervention with drugs may reduce or prevent the development of new heart failure; (2) use novel drugs, devices and stem cell therapies to identi ....Heart failure describes where the heart cannot pump adequately to meet the needs of the body. This condition has a high mortality despite recent advances in therapy, therefore, there is an urgent need for new approaches to this condition. The present grant aims to: (1) identify patients at high-risk for future development of this condition where early intervention with drugs may reduce or prevent the development of new heart failure; (2) use novel drugs, devices and stem cell therapies to identify ways to better treat patients with existing disease; (3) focus on the effect of heart failure on the kidney and vice versa via early diagnosis and treatment strategiesRead moreRead less
The team has been at the forefront of research on type 1 diabetes for over a decade. This form of diabetes is a major chronic disease from childhood, as well as accounting for at least 10% of adult-onset diabetes. It occurs when the body�s immune system attacks and destroys the beta cells in the pancreas that make insulin, the hormone that controls the level of glucose in the blood. The team was one of the first in the world, and is the only one in Australia, to develop screening programs to tes ....The team has been at the forefront of research on type 1 diabetes for over a decade. This form of diabetes is a major chronic disease from childhood, as well as accounting for at least 10% of adult-onset diabetes. It occurs when the body�s immune system attacks and destroys the beta cells in the pancreas that make insulin, the hormone that controls the level of glucose in the blood. The team was one of the first in the world, and is the only one in Australia, to develop screening programs to test and identify people at risk for type 1 diabetes. They showed that the underlying disease could start years before symptoms occurred and discovered genes that determine the rate at which the underlying disease progresses. They have also found evidence that the disease may be triggered by gut viruses called rotaviruses in genetically-susceptible individuals. They showed that type 1 diabetes could be prevented in a mouse model by getting the immune system to make a protective response to insulin, and then went on to apply this in at-risk humans in a controlled trial of intranasal insulin, the first of its kind. They have used genetic techniques not only to pinpoint the mechanisms responsible for killing the beta cells but also to modify the beta cells to make them resistant to attack by these mechanisms. The multidisciplinary approach of the team will be directed to further understanding the genetic and environmental factors underlying type 1 diabetes and the immune mechanisms, particularly involving special white blood cells called T cells, that kill beta cells. A molecular target of the immune attack, the parent of insulin called proinsulin, will be used, paradoxically, as a tool to regulate the immune system and avert the attack. This will be achieved by giving proinsulin via the mucosa of the naso-respiratory tract or via the bone marrow-derived stem cells, initiallyin the mouse model as a test of feasibility for human application. In parallel with these approaches to prevention, specially constructed viruses will be used to transfer several new genes into beta cells to improve their resistance to immune attack, so that they can be transplanted into people with established diabetes without the need for potentially toxic drugs that suppress the immune system overall. The integrated research of the team is helping to provide a sound, rational base for the eventual prevention and cure of type 1 diabetes.Read moreRead less
Type 1 diabetes (T1D) is a major chronic disease affecting over 100,000 Australians. Its treatment and complications impose a significant burden on affected individuals and their families and on the health system. T1D occurs when the immune system attacks insulin-producing cells in the islet cells of the pancreas. The team has developed ways to identify at-risk people, defined immune and genetic causes of T1D and is undertaking prevention trials and Australia's first islet transplant program. Th ....Type 1 diabetes (T1D) is a major chronic disease affecting over 100,000 Australians. Its treatment and complications impose a significant burden on affected individuals and their families and on the health system. T1D occurs when the immune system attacks insulin-producing cells in the islet cells of the pancreas. The team has developed ways to identify at-risk people, defined immune and genetic causes of T1D and is undertaking prevention trials and Australia's first islet transplant program. Their multidisciplinary research is taking us closer to the prevention and cure of T1D.Read moreRead less
Advances In Clinical Trials Research And Evidence Based Decision Making
Funder
National Health and Medical Research Council
Funding Amount
$6,712,859.00
Summary
The NHMRC Clinical Trials Centre at the University of Sydney aims to use clinical trials and methodological research in trials to improve health in Australia and internationally It is a member of many international collaborative trials groups, especially in heart disease and cancer. A particular area of interest is patient preferences and decision making, particularly in cancer. The Clinical Trial Centre is active in using data from its own and other clinical trials in combined analyses to arriv ....The NHMRC Clinical Trials Centre at the University of Sydney aims to use clinical trials and methodological research in trials to improve health in Australia and internationally It is a member of many international collaborative trials groups, especially in heart disease and cancer. A particular area of interest is patient preferences and decision making, particularly in cancer. The Clinical Trial Centre is active in using data from its own and other clinical trials in combined analyses to arrive at better evidence.Read moreRead less
Generating The Evidence For New Strategies To Combat Cardiovascular Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$12,809,917.00
Summary
The Program brings together clinicians, epidemiologists and statisticians in a unique endeavour combating heart attack and stroke. For the foreseeable future, these conditions will remain leading causes of death and disease in Australia and the world. While there are many established treatment and prevention strategies there remains great potential for further advances to avert large numbers of deaths and serious disabling outcomes. This Program will provide new information that will give patien ....The Program brings together clinicians, epidemiologists and statisticians in a unique endeavour combating heart attack and stroke. For the foreseeable future, these conditions will remain leading causes of death and disease in Australia and the world. While there are many established treatment and prevention strategies there remains great potential for further advances to avert large numbers of deaths and serious disabling outcomes. This Program will provide new information that will give patients, doctors, consumers and policy makers new options for disease prevention.Read moreRead less
Type 2 diabetes (T2D) is threatening the health of this nation and if unchecked will cripple our health care system. There are several problems: (1) The incidence of T2D is growing and we do not fully know why; (2) T2D involves defective insulin action but how insulin works normally is still unclear; (3) much research in this area is performed in laboratory cells or animals and the translation of this research to the human disease is yet to be fully realised; and (4) current therapies and diagno ....Type 2 diabetes (T2D) is threatening the health of this nation and if unchecked will cripple our health care system. There are several problems: (1) The incidence of T2D is growing and we do not fully know why; (2) T2D involves defective insulin action but how insulin works normally is still unclear; (3) much research in this area is performed in laboratory cells or animals and the translation of this research to the human disease is yet to be fully realised; and (4) current therapies and diagnostic markers for early disease prediction are inadequate. Our goal is to make progress in each of these areas.Read moreRead less
Integration Of Risk Evaluation In Cardiovascular Disease Management Programs.
Funder
National Health and Medical Research Council
Funding Amount
$5,162,176.00
Summary
This study will determine the feasibility of a coordinated health care team approach to the treatment of cardiovascular disorders. It will examine a range of issues – who would most benefit from this approach, its value for money, the relative importance of health care services to consumers, and where to invest additional health funds. Built on strong collaborations between expert researchers in advanced diagnostic techniques, coordinated health care, community health care and health economics, ....This study will determine the feasibility of a coordinated health care team approach to the treatment of cardiovascular disorders. It will examine a range of issues – who would most benefit from this approach, its value for money, the relative importance of health care services to consumers, and where to invest additional health funds. Built on strong collaborations between expert researchers in advanced diagnostic techniques, coordinated health care, community health care and health economics, this provides a unique opportunity to benefit millions of Australians.Read moreRead less
Muscularskeletal Pain, Injury And Health: Improving Outcomes Through Conservative Management
Funder
National Health and Medical Research Council
Funding Amount
$8,123,518.00
Summary
Musculoskeletal pain and injury is a major health issue facing our ageing society. The cost in terms of health care and lost productivity is second only to cardiovascular disease. This Program will address the major musculoskeletal disorders such as spinal pain and osteoarthritis. The team will undertake research with the potential for real and enduring impact on these conditions - from the physiological basis for their occurrence, to trials of innovative drug-free conservative treatments.
Patient Safety: Enabling And Supporting Change For A Safer And More Effective Health System
Funder
National Health and Medical Research Council
Funding Amount
$8,878,409.00
Summary
Internationally, patient safety is a growing concern. Patient harm occurs in 10% of hospital admissions. A million adverse events occur in general practice each year in Australia. Overseas data reports that patients receive recommended care only 50% of the time. We will significantly advance this work by investigating how and why this ccurs, with a focus on the roles of teamwork, safe medication use and the application of information technology to support improved decision-making.